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Abstract
Background: To estimate the effectiveness of routine antenatal anti-D prophylaxis for preventing sensitisation in pregnant
Rhesus negative women, and to explore whether this depends on the treatment regimen adopted.
Methods: Ten studies identified in a previous systematic literature search were included. Potential sources of bias were
systematically identified using bias checklists, and their impact and uncertainty were quantified using expert opinion. Study
results were adjusted for biases and combined, first in a random-effects meta-analysis and then in a random-effects meta-
regression analysis.
Results: In a conventional meta-analysis, the pooled odds ratio for sensitisation was estimated as 0.25 (95% CI 0.18, 0.36),
comparing routine antenatal anti-D prophylaxis to control, with some heterogeneity (I2 = 19%). However, this naı¨ve analysis
ignores substantial differences in study quality and design. After adjusting for these, the pooled odds ratio for sensitisation
was estimated as 0.31 (95% CI 0.17, 0.56), with no evidence of heterogeneity (I2 = 0%). A meta-regression analysis was
performed, which used the data available from the ten anti-D prophylaxis studies to inform us about the relative
effectiveness of three licensed treatments. This gave an 83% probability that a dose of 1250 IU at 28 and 34 weeks is most
effective and a 76% probability that a single dose of 1500 IU at 28–30 weeks is least effective.
Conclusion: There is strong evidence for the effectiveness of routine antenatal anti-D prophylaxis for prevention of
sensitisation, in support of the policy of offering routine prophylaxis to all non-sensitised pregnant Rhesus negative women.
All three licensed dose regimens are expected to be effective.
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Introduction
Women who are Rhesus negative require particular antenatal
care and monitoring during pregnancy. If the fetus carried is
Rhesus positive, there is a risk that mixing of fetal and maternal
blood cells will lead to the woman becoming sensitised, which may
cause fetuses in any subsequent pregnancies to suffer from
haemolytic disease of the newborn [1]. Women in developed
countries have long been offered targeted anti-D immunoglobulin
with the aim of preventing sensitisation, after the birth of a Rhesus
positive baby and after other potentially sensitising events such as
miscarriage, termination of pregnancy or amniocentesis [2].
Under this policy, the incidence of haemolytic disease of the
newborn was substantially reduced but was still believed to cause
death in 6 out of 100 000 live births [3]. The UK National
Institute for Health and Clinical Excellence (NICE) evaluated, first
in 2003 and subsequently updated in 2009, the potential benefits
from offering routine antenatal anti-D prophylaxis (RAADP) to all
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non-sensitised Rhesus negative pregnant women [4,5]. In both
evaluations, it was concluded that RAADP was cost-effective and
should be delivered to all non-sensitised Rhesus negative pregnant
women. The second NICE report recommended further research
to compare the effectiveness of the different licensed RAADP
regimens, since the available studies provided insufficient evidence
to inform a treatment comparison [5]. Two of the three licensed
regimens have not yet been evaluated in practice. However,
published studies provide evidence on the effectiveness of dose
regimens similar to the two unevaluated regimens, and on the
third licensed regimen directly.
The NICE appraisals identified 10 studies which evaluated the
clinical effectiveness of RAADP compared to control [6–15].
However, the studies were generally of poor quality and varied
substantially in study design. For example, many of the studies used
historical rather than concurrent controls, only one study was
randomised, and there were often post-hoc exclusions and large
numbers of women lost to follow-up. Across the 10 studies, there
were differences in the doses and timing of administering anti-D
immunoglobulin, in the obstetric characteristics of the women
recruited to each study, and in the follow-up times. Differences in
study design and methodological limitations make it inappropriate
to use a conventional meta-analysis to combine the study results and
draw overall conclusions. In the NICE appraisals, conclusions on
clinical effectiveness and cost-effectiveness were therefore based
primarily on a meta-analysis of only the two studies considered to be
most relevant to the UK setting and of acceptable quality [12,13].
There are two major weaknesses of conventional meta-analysis.
First, by excluding trials which fall below an arbitrary threshold of
quality, some of the available evidence is ignored. Second, by
simply pooling the results of studies above the threshold, known
biases in these studies are not accounted for. Methodological
quality is assessed by the majority of systematic review authors
[16], but only about 50% make use of the quality assessment,
usually in sensitivity analyses or subgroup analyses [17]. In
general, the primary results presented from a meta-analysis make
no allowance for differences in quality or design among the studies
included. It is misleading to report confidence intervals which
represent only the uncertainty due to random error when
systematic biases are suspected [18].
Recently, four of the authors of this paper proposed methods for
performing bias-adjusted meta-analysis, enabling adjustment for
differences in quality and design [19]. The advantages of bias-
adjusted meta-analysis are that all available evidence can be
synthesised and that the analysis allows for biases present in the
studies. To exemplify the methods, the previous paper demonstrat-
ed their application to 8 of the anti-D studies [19]. However, the
bias adjustment process was carried out for illustrative purposes in
our earlier paper, without the involvement of experts on anti-D
prophylaxis, and the results were not intended to inform clinical
practice. In the present paper, we have obtained new pooled bias-
adjusted results for the effectiveness of RAADP, based on a synthesis
of all 10 available studies. The impact of differences in dose
regimen, follow-up times and study populations was evaluated by
assessors with knowledge of anti-D prophylaxis, while the impact of
methodological flaws in the studies was evaluated by assessors with
quantitative expertise. To inform the analysis comparing different
RAADP dose regimens, we also elicited opinion on the relative
effectiveness of all treatment regimens of relevance, comprising the
five treatments evaluated in one or more studies and the two
treatments which are licensed but as yet unevaluated. A meta-
regression was performed to estimate the association between the
observed effectiveness of different anti-D dose regimens and pooled
opinion on the effectiveness of each regimen relative to an optimally
effective treatment. This enabled estimation of the differences in
effectiveness between all three licensed dose regimens of anti-D
immunoglobulin, which has not been possible previously.
Methods
Source studies
The analyses presented included the studies identified through
systematic literature searches in the two UK NICE technology
appraisals of RAADP [4,5]. The first NICE appraisal identified 10
studies which compared RAADP to control [6–15]. The second
appraisal identified only one new relevant study, which compared
intravenous against intramuscular delivery of the same dose of
RAADP. Two of the original 10 studies comparing RAADP to
control were excluded from the second NICE appraisal, since
these evaluated doses which were unlicensed in the UK. In the
primary analyses presented in this paper, all 10 studies comparing
RAADP to control were included. Amongst these ten, three studies
[6–8] by Bowman and colleagues used the same group of women
as controls. The later two studies were not strictly comparative
studies, since the focus in each of them was on describing a new
treated group of women. However, these two studies are useful in
providing evidence on the effectiveness of a single high dose of
RAADP. In most analyses we included all three Bowman studies,
but in a sensitivity analysis we excluded the later two.
Bias-adjustment method
A recently proposed meta-analytic method [19] allows adjust-
ment for both methodological limitations (internal biases) in the set
of studies to be combined and differences in study design relative to
the research question of interest (external biases). The method was
implemented using the following steps, which we discuss further
below: define the target setting; describe an idealised version of each
available study; identify internal and external biases; elicit expert
opinion on the magnitude and uncertainty of the biases; perform a
bias-adjusted meta-analysis. To demonstrate the methods, we use
the study by Trolle [15], which evaluated a dose of 1500 IU anti-D
immunoglobulin at 28 weeks’ gestation, in non-sensitised pregnant
Rhesus negative women attending a Danish hospital.
We use the term ‘‘target setting’’ to refer to the research
question of interest. In our evaluation of the effectiveness of
RAADP, the target setting reflects the objectives of the first NICE
appraisal in terms of the population to which the findings will be
applied, the intervention and control policies being compared, and
the outcome of interest. These were defined as:
(i) Population: Non-sensitised pregnant Rhesus negative
women in the UK
(ii) Intervention: Dose of 500 IU anti-D immunoglobulin
offered intramuscularly at 28 and 34 weeks’ gestation, in
addition to control antenatal care
(iii) Control: Anti-D immunoglobulin offered postpartum and
after potentially sensitising events during pregnancy,
according to 2002 UK policy
(iv) Outcome: Prevention of Rhesus sensitisation which would
affect a subsequent pregnancy
The next step in the bias-adjustment process was to define an
idealised version of each study included in the meta-analysis. The
idealised study is an imagined repeat of the original study, in which
the design would be modified to eliminate all sources of internal
bias (i.e. methodological limitations). The protocol for an idealised
study is a tool which helps us identify internal and external biases
in the original study, and the design need not be practically
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possible. As an example, we present the protocol for an idealised
version of Trolle [15].
(i) Population: Non-sensitised Rhesus negative women deliv-
ered of Rhesus positive babies at Kolding Hospital,
Denmark
(ii) Intervention: Dose of 1500 IU anti-D immunoglobulin
given at 28 weeks’ gestation, in addition to control
antenatal care
(iii) Control: Dose of at least 1000 IU anti-D immunoglobulin
given postpartum and anti-D offered after potentially
sensitising events during pregnancy.
(iv) Outcome: Sensitisation at 10 months postpartum
This protocol describes the intended population, intervention
strategy, control strategy and outcome in the Trolle study,
according to the published study report [15]. The actual study
differed from the imagined idealised study in several respects,
which will be discussed later in the paper.
To identify internal biases in the 10 studies of the effectiveness
of RAADP, we compared each study against its idealised version.
An internal bias checklist was completed for each study. This
entailed answering a series of questions about potential sources of
bias, and summarising relevant details extracted from the original
papers. Following the methodology of Turner et al. [19], we
considered the following five categories of internal bias: biases
caused by differences between intervention and control groups at
baseline (‘‘selection bias’’); biases related to lack of blinding of
participants or caregivers (‘‘performance bias’’); biases caused by
exclusions and drop-outs (‘‘attrition bias’’); biases related to
measurement of the outcome (‘‘outcome bias’’) and additional
biases (‘‘other bias suspected’’).
To identify external biases, we compared the idealised versions
of the RAADP studies against the target setting. An external bias
checklist was completed for each study. We considered the
following four categories of external bias: biases caused by
differences between the idealised study population and target
population of non-sensitised pregnant Rhesus negative women in
the UK (‘‘population bias’’); differences between the study and
target interventions (‘‘intervention bias’’); differences between the
study and target control strategies (‘‘control bias’’); and differences
between the outcome measured in the study and the target
outcome, sensitisation which would affect a subsequent pregnancy
(‘‘outcome bias’’).
Bias assessment
Internal biases were assessed by four assessors with quantitative
expertise (three biostatisticians and one obstetrician), and external
biases were assessed separately by four assessors selected for their
knowledge of anti-D prophylaxis. At the elicitation meetings, the
assessors discussed each study in turn and reviewed the bias
checklist, while discussing any queries and resolving misunder-
standings. For each bias, assessors agreed whether the bias would
change only the magnitude of the intervention effect (a
proportional bias) or whether it could change the direction of
effect (an additive bias). After the group discussion, the assessors
independently gave their opinions on the magnitude (and
uncertainty) of each bias in each study, by marking ranges on
bias elicitation scales (Figure 1). Opinions about the size and
uncertainty in the biases were marked using 67% intervals, such
that the assessor believed the true bias was twice as likely to lie
inside rather than outside this range. For example, if the assessor
believed that a study with historical controls was likely to be
subject to a major additive internal selection bias favouring
RAADP, then a 67% interval might be indicated as 0.4 to 0.8 on
the left-hand side of the upper scale in Figure 1. If the assessor
believed that a study of primigravidae was almost entirely relevant
to all non-sensitised pregnant women, then an interval of 0.9 to 1/
0.9 might be indicated for a proportional external population bias
on the lower scale.
Bias-adjusted meta-analysis
For each assessor, we calculated means and variances for total
bias in each study, for additive and proportional biases separately.
These were used to adjust the study effect estimates and standard
errors for bias, while acknowledging the uncertainty about the
extent of bias [19]. For each study, results were pooled across
assessors by taking the medians of the assessors’ adjusted estimates
and standard errors, in order to obtain the opinion of a ‘‘typical’’
assessor [20]. Finally, a conventional random-effects meta-analysis
was used to combine the bias-adjusted results across studies.
Statistical heterogeneity was assessed using the I2 statistic [21],
which gives the percentage of variation between the study
estimates attributable to true between-study heterogeneity rather
than random variation; 0% indicates no heterogeneity.
Analysis comparing different dose regimens
In a meta-regression analysis, we used the data available from
the RAADP studies to inform us about the relative effectiveness of
three anti-D dose regimens which were of particular interest in the
second NICE appraisal. These are the three licensed anti-D
treatments: 500 IU at 28 and 34 weeks; 1500 IU at 28–30 weeks;
1250 IU at 28 and 34 weeks. Four of the RAADP studies
evaluated the effectiveness of the first of these [10,12–14], but no
studies have evaluated either of the latter two treatments exactly as
specified. In principle, it would be possible to use the available
study data to compare the effectiveness of giving 500 IU at 28 and
34 weeks with the effectiveness of giving 1500 IU at 28 weeks
(evaluated in three studies [7,8,15]) or 1500 IU at 28 and 34 weeks
(evaluated in one study [6]). However, the small number of studies
means that differences between dose regimens would be very
imprecisely estimated. Subgroup analyses comparing the effects of
different doses cannot provide any conclusive findings in this data
set.
We therefore elicited opinion on the relative effectiveness of all
RAADP treatment regimens of relevance, comprising the five
treatments evaluated in one or more studies and the two
treatments which are licensed but as yet unevaluated. For each
treatment regimen, four assessors with knowledge of anti-D
prophylaxis were asked to provide numerical 67% ranges to
describe their belief and uncertainty about the effectiveness of this
treatment relative to an imagined optimally effective treatment (i.e.
one which would prevent all sensitisations during pregnancy).
Assessors were asked to take into account the half-life of
prophylactic anti-D (approximately 3 weeks), the minimum
circulating level required to provide protection against sensitisa-
tion, and anticipated compliance with each treatment regime.
Pilgrim et al. [5] noted that compliance may be greater for a
single-dose regimen for logistical reasons, but also that a two-dose
regimen offers an opportunity to reduce the risk somewhat if the
first appointment is missed.
Values on the elicitation scale for relative effectiveness ranged
from 0 for a treatment no better than control to 1 for an optimally
effective treatment. A meta-regression analysis [22] was performed
to estimate the association between the measure of relative
effectiveness (as a predictor measured with uncertainty) and the
observed effectiveness of the five treatments on which data are
available. The observed odds ratios were first adjusted for all
Effectiveness of Antenatal Anti-D Prophylaxis
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Figure 1. Elicitation scales. Elicitation scales for quantifying additive biases on a relative risk scale and for quantifying proportional biases as
proportional change to (log) relative risk.
doi:10.1371/journal.pone.0030711.g001
Table 1. Summary of characteristics of studies comparing RAADP to control, with reported odds ratios for sensitisation.
Study Population Intervention Control Outcome OR (95% CI)
Bowman (1) [6] Non-sensitised Rh2 women
delivered of Rh+ babies in a
Canadian province
Two doses of 1500 IU anti-D
Ig, given at 28 and 34 weeks’
gestation, in addition to
control care
1500 IU anti-D Ig given
within 72 hours after
delivery of a Rh+ baby
or abortion
Sensitisation during
pregnancy or within
3 days after delivery
0.02 (0.001, 0.33)
Bowman (2) [7] Non-sensitised Rh2 women
delivered of Rh+ babies in a
Canadian province
One dose of 1500 IU anti-D
Ig, given at 28 weeks’ gestation,
in addition to control care
1500 IU anti-D Ig given
within 72 hours after
delivery of a Rh+ baby
or abortion
Sensitisation at
delivery
0.34 (0.18, 0.65)
Bowman (3) [8] Non-sensitised Rh2 women
delivered of Rh+ babies in a
Canadian province
One dose of 1500 IU anti-D
Ig, given at 28 weeks’ gestation,
in addition to control care
1500 IU anti-D Ig given
within 72 hours after
delivery of a Rh+ baby
or abortion
Sensitisation at
delivery
0.18 (0.12, 0.28)
Hermann [9] Non-sensitised Rh2 women
delivered of Rh+ babies at a
Swedish hospital
One dose of 1250 IU anti-D Ig,
given at 32–34 weeks’ gestation,
in addition to control care
1250 IU anti-D Ig given
within 72 hours after
delivery of a Rh+ baby
Sensitisation at 8
months postpartum
0.24 (0.05, 1.10)
Huchet [10] Rh2 primiparae delivered
of Rh+ babies in 23
Parisian maternity units
Two doses of 500 IU anti-D
Ig, given at 28 and 34 weeks’
gestation, in addition to
control care
500 IU anti-D Ig given
after delivery of a Rh+
baby, repeated if
necessary
Sensitisation at 2–12
months postpartum
0.14 (0.02, 1.14)
Lee [11] Rh2 primigravidae
delivered of Rh+ babies
in several UK obstetric
units
Two doses of 250 IU anti-D Ig,
given at 28 and 34 weeks’
gestation, in addition to
control care
Anti-D Ig given after
delivery and after
potentially sensitising
events ‘‘in the usual way’’
(UK, 1992), doses not stated
Sensitisation at 6
months postpartum
0.56 (0.14, 2.24)
MacKenzie [12] Non-sensitised Rh2
primiparae delivered of
Rh+ babies in two
UK counties
Two doses of 500 IU anti-D Ig,
given at 28 and 34 weeks’
gestation, in addition to
control care
‘‘Standard’’ anti-D
prophylaxis given after
delivery and after
potentially sensitising
events (UK, 1990–1996),
doses not stated
Sensitisation during
second pregnancy
0.44 (0.22, 0.86)
Mayne [13] Rh2 primigravidae
delivered of Rh+
babies in
Derbyshire, UK
Two doses of 500 IU anti-D Ig,
given at 28 and 34 weeks’
gestation, in addition to
control care
No information provided
on control care; study
setting was UK, 1988–1990
Sensitisation
during second or
subsequent
pregnancy
0.25 (0.08, 0.74)
Tovey [14] Rh2 primigravidae
delivered of Rh+
babies in Yorkshire,
UK
Two doses of 500 IU anti-D Ig,
given at 28 and 34 weeks’
gestation, in addition to
control care
500 IU anti-D Ig given
after delivery of a Rh+
baby, or a higher dose
if the Kleihauer count
was abnormal
Sensitisation in
a subsequent
pregnancy
0.16 (0.04, 0.67)
Trolle [15] Non-sensitised Rh2
women delivered
of Rh+ babies at a
Danish hospital
One dose of 1500 IU anti-D Ig,
given at 28 weeks’ gestation,
in addition to control care
1000 IU anti-D Ig given
after delivery of a
Rh+ baby
Sensitisation at 10
months postpartum
0.08 (0.005, 1.49)
doi:10.1371/journal.pone.0030711.t001
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internal and external biases except Intervention bias. The fitted
model was then used to predict the underlying effectiveness odds
ratio expected in a future study of any of the seven treatments,
including the two on which no direct data are available.
Results
Study characteristics and extracted results
The designs of the ten RAADP studies included in our analyses
are summarised in Table 1. The anti-D prophylaxis regimen
administered to women in the intervention group varied across
studies. Anti-D was given on either one or two occasions, and
doses and planned timing of routine prophylaxis differed. There
was also substantial variation in the time at which women were
followed up for sensitisation to Rhesus positive antibodies.
Sensitisation can be most accurately assessed in a subsequent
pregnancy [5], as in the MacKenzie [12] and Mayne [13] studies,
but some studies assessed sensitisation immediately after each
woman’s first delivery or at 6–12 months postpartum. The study
populations varied somewhat across studies in terms of both their
geographical locations, and the fact that some studies included
non-sensitised multigravidae as well as primigravidae.
Table 1 presents the odds ratios extracted from each study,
comparing RAADP to control. Six of the studies found evidence of
a lower sensitisation rate in women who received RAADP. Odds
ratio estimates in the other four studies were also well below 1, but
the associated confidence intervals were wide as a consequence of
small sample sizes. Substantial differences in design mean that a
Table 2. Potential internal biases identified in the studies.
Study Selection bias Performance bias Attrition bias Outcome bias
Bowman (1) [6] Historical controls used,
and location of women
recruited also differed to
some extent between groups.
Confounding not addressed.
No blinding, so the likelihood
of receiving directed anti-D
after potentially sensitising
events may differ between groups.
Unclear – losses to
follow-up not reported.
Suggestion that outcome
assessors couldn’t
distinguish between immune
and passive antibodies.
Bowman (2) [7] Historical controls used
in comparison between
groups. Confounding
not addressed.
No blinding, so the likelihood
of receiving directed anti-D
after potentially sensitising
events may differ between groups.
Unclear – losses to
follow-up not reported.
Suggestion that outcome
assessors couldn’t distinguish
between immune and passive
antibodies in control group.
Bowman (3) [8] Historical controls used
in comparison between
groups. Confounding
not addressed.
No blinding, so the likelihood
of receiving directed anti-D
after potentially sensitising
events may differ between groups.
Unclear – losses to
follow-up not reported.
Suggestion that outcome
assessors couldn’t distinguish
between immune and passive
antibodies in control group.
Hermann [9] Historical controls used, and
very little information on
inclusion/exclusion criteria.
Confounding not addressed.
No blinding, so the likelihood
of receiving directed anti-D
after potentially sensitising
events may differ between groups.
Some posthoc exclusions
in intervention group. No
information on losses to
follow-up or exclusions
in control group.
Suggestion that outcome
assessors couldn’t
distinguish between immune
and passive antibodies.
Huchet [10] Contemporary controls used,
but allocation to groups was
non-random. Confounding
not addressed.
No blinding, so the likelihood
of receiving directed anti-D
after potentially sensitising
events may differ between
groups.
4% of women lost to
follow-up after recruitment.
No outcome available for
21% of remaining treated
women and 21% of controls.
Lee [11] No blinding, so the likelihood
of receiving directed anti-D
after potentially sensitising
events may differ between groups.
21% of treated women and
16% controls lost to follow-up
after recruitment. No outcome
available for 32% of remaining
treated women and 38% of
controls.
MacKenzie [12] Contemporary controls used,
but location of women recruited
differed between groups.
Confounding not addressed.
No blinding (as above). No
individual follow-up, so women
migrating into intervention
group area may not have
received routine anti-D in
first pregnancy.
Unclear – insufficient details
on how sensitisation rates
in the two groups were
determined.
Mayne [13] Historical controls used.
Confounding not addressed.
No blinding (as above). No
individual follow-up, so women
migrating into intervention
group area may not have received
routine anti-D in first pregnancy.
Unclear – insufficient
details on how sensitisation
rates in the two groups
were determined.
Tovey [14] Historical controls used.
Confounding not addressed.
No blinding (as above). Unclear – losses to
follow-up not reported.
Trolle[15] Historical controls used.
Treated group excludes
sensitised women at 28
weeks, but control group
does not. Confounding
not addressed.
No blinding (as above). In
addition, some controls may
not have received anti-D after
delivery, as control period predates
routine use of anti-D in Denmark.
16% of treated women
and 9% controls lost to
follow-up.
Possibility that outcome
assessors couldn’t distinguish
between immune and passive
antibodies.
doi:10.1371/journal.pone.0030711.t002
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simple meta-analysis would be inappropriate, and the many
methodological limitations in the studies would make interpreta-
tion problematic. We addressed these issues by performing a bias-
adjusted meta-analysis.
Biases identified
The potential internal biases affecting each of the 10 studies, as
identified through completion of an internal bias checklist, are
summarised in Table 2. Selection bias was a major concern in
seven studies, since women receiving RAADP were compared to
historical controls who were very likely to have differed from the
intervention women in many respects, and the statistical analyses
did not adjust for confounding. The lack of blinding (which would
be difficult in this setting for ethical reasons) of both subjects and
caregivers means that the chance of receiving directed anti-D after
a potentially sensitising event possibly differed between interven-
tion and control groups in all studies. In addition, there were losses
to follow-up, although not all studies provided information on this,
and there were problems with assessing sensitisation accurately in
a few of the earliest studies.
External biases arose from differences between the available
RAADP studies and the pre-defined target setting with respect to
population, intervention, control strategy and the outcome
measure (Table 1).
Figure 2. Biases in the Trolle study. (a) 67% ranges elicited from assessors A–D for additive internal biases, with means and 67% ranges for total
internal bias; (b) 67% ranges elicited from assessors E–H for proportional external biases, with means and 67% ranges for total external bias.
doi:10.1371/journal.pone.0030711.g002
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Bias-adjusted results for one study
To exemplify the methods, we first discuss bias adjustment in
the Trolle study [15]. The bias assessments provided by individual
bias assessors for internal and external biases in this study are
presented in Figure 2. In this study, all internal biases were
regarded as additive and all external biases were regarded as
proportional. Two of the biases (selection bias and performance
bias) were expected by all assessors to make the intervention
appear more effective. Selection bias was caused by use of
historical controls and inclusion policies which differed between
the intervention and control groups (Table 2). Performance bias
was caused by lack of blinding and the possibility that some
women in the control group did not receive anti-D postpartum.
There was a general degree of consistency among the four
assessors’ opinions on the internal biases.
There was more variation in assessors’ opinions on the external
biases. Most assessors were uncertain whether the difference
between the intervention evaluated by Trolle and the target
intervention would cause the intervention effect to be exaggerated
or reduced. All assessors believed that the difference between
antenatal care received by the control group in the Trolle study
and antenatal care in the target control setting would lead to an
exaggerated effect. By measuring the outcome at 10 months
postpartum, the Trolle study may have failed to detect some
sensitisations which would only become obvious in a subsequent
pregnancy. Three assessors expected that this was likely to cause
an exaggerated effect in the Trolle study relative to a study
measuring the target outcome of sensitisation in a subsequent
pregnancy, while one assessor expected a reduced effect.
The impact of adjusting the Trolle results for (a) internal biases
and (b) external biases is shown in Figure 3. Since internal biases
were believed to have favoured the intervention group, the bias-
adjusted odds ratio has shifted towards the null value 1. External
biases were generally expected to have caused an exaggerated
effect in the Trolle study compared to the target setting, so
adjustment for these also caused a shift towards 1. The width of
the 95% confidence interval for the odds ratio was not much
affected by the adjustment for bias and its uncertainty, because the
unadjusted estimate was already imprecise in this study.
Bias-adjusted meta-analysis results
In a bias-adjusted meta-analysis of the ten RAADP studies, the
pooled odds ratio for sensitisation was estimated as 0.31 (95% CI
0.17, 0.56), with no evidence of heterogeneity (I2 = 0%). This result
provides strong evidence for the effectiveness of RAADP in
preventing sensitisation of pregnant Rhesus negative women. We
compare this result with the clinical effectiveness findings in the
two NICE appraisals [4,5], which did not include a quantitative
synthesis of all evidence. In both NICE appraisals, the principal
clinical findings were based on a fixed effect meta-analysis of two
studies, MacKenzie [12] and Mayne [13], which were considered
to be most relevant to the UK setting and of higher quality.
Pooling the results of these two studies (with no adjustment for
bias) gave an odds ratio for sensitisation of 0.37 (95% CI 0.21,
0.65). This is similar to the result from the bias-adjusted meta-
analysis including all 10 studies, and we note that the MacKenzie
and Mayne studies received highest weight in our analysis, 31%
and 14% respectively.
To illustrate the impact of our bias adjustments on the results of
the 10 studies, Figure 4 presents three versions of the meta-analysis:
first unadjusted, secondly adjusted for internal biases and thirdly
adjusted additionally for external biases. After adjusting for internal
and external biases, all but one of the study estimates shifted towards
the null value 1, and most confidence intervals widened to reflect
increased uncertainty about results affected by biases. A naı¨ve
conventional random-effects meta-analysis of all 10 studies
produced a pooled odds ratio of 0.25 (95% CI 0.18, 0.36),
comparing RAADP to control, with some heterogeneity (I2 = 19%).
This result does not acknowledge the uncertainty caused by biases,
so the confidence interval is inappropriately narrow. After adjusting
Figure 3. Impact of adjusting for internal and external bias in the Trolle study. Impact of adjusting initially for internal bias and
subsequently for both internal and external bias (using pooled internal bias-adjusted results) on the odds ratio (and 95% interval), for each assessor
separately and combined using median pooling.
doi:10.1371/journal.pone.0030711.g003
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for internal biases, the pooled odds ratio for sensitisation was
estimated as 0.28 (95% CI 0.15, 0.53), comparing RAADP to
control, and there was no remaining evidence of between-study
heterogeneity (I2 = 0%). This result allows for the methodological
limitations in the RAADP studies, but does not acknowledge their
varying relevance to the target setting of interest to NICE.
As a sensitivity analysis, we also present results from a meta-
analysis excluding the Bowman (2) and Bowman (3) studies [7,8],
which share a control group with Bowman (1) [6]. In a bias-
adjusted meta-analysis of these 8 studies, the pooled odds ratio for
sensitisation was estimated as 0.31 (95% CI 0.16, 0.61), with no
evidence of heterogeneity (I2 = 0%). The numerical result is similar
to that based on all 10 studies and the conclusions from the
analysis are unchanged. To check the robustness of our findings,
we also performed separate meta-analyses using the opinions of
each assessor in turn. The results obtained from adjusting for the
opinions of each internal bias assessor were similar to each other
and close to results adjusted for pooled opinion on internal bias.
Meta-analyses adjusted for each external bias assessor in turn
(following adjustment for pooled opinion on internal bias) were
also similar to each other and close to the pooled bias-adjusted
meta-analysis.
Analysis comparing different dose regimens
In a meta-regression analysis, we estimated the association
between the observed results for each anti-D dose in the studies
available and the pooled opinion on a measure of relative
effectiveness of each dose (Figure 5). Within this analysis, we
predicted the underlying odds ratios we would expect for each of
the three licensed anti-D treatments, in a new study evaluating
their effectiveness compared to control (without allowance for
sampling variation). The estimated odds ratios for sensitisation are
0.31 (95% CI 0.09, 0.65) for a dose of 500 IU at 28 and 34 weeks,
0.42 (95% CI 0.17, 0.73) for a dose of 1500 IU at 28–30 weeks,
and 0.18 (95% CI 0.03, 0.53) for a dose of 1250 IU at 28 and 34
weeks. Using the data available for other doses of anti-D and the
beliefs on relative effectiveness elicited from four assessors, we have
estimated odds ratios for the effectiveness of two licensed
treatments which have not yet been evaluated. Each of the two
unevaluated treatments is expected to be effective for prevention of
sensitisation. Among the three licensed treatments, the estimated
probability that a dose of 1250 IU at 28 and 34 weeks is most
effective is 83%, while the probability that a dose of 500 IU at 28
and 34 weeks is most effective is 15%. The probability that a single
dose of 1500 IU at 28–30 weeks is least effective amongst these
three regimens is estimated as 76%.
Discussion
A bias-adjusted meta-analysis allowed us to synthesise all
available evidence on the effectiveness of RAADP, while adjusting
for differences in study quality and design. The pooled bias-
adjusted results presented here provide strong evidence that
RAADP prevents sensitisation in pregnant Rhesus negative
women. These findings confirm the conclusions of the two NICE
appraisals, which did not include a quantitative synthesis of all
evidence. It is reassuring to find that, when all evidence on clinical
effectiveness is taken into account, the widespread policy of
Figure 4. Impact of adjusting for bias in the meta-analysis of 10
studies comparing RAADP to control. (a) unadjusted odds ratios
(with 95% CIs); (b) odds ratios adjusted for internal biases (with 95%
CIs); (c) odds ratios adjusted for all biases (with 95% CIs).
doi:10.1371/journal.pone.0030711.g004
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offering RAADP to all non-sensitised pregnant Rhesus negative
women remains strongly supported. However, the cost-effective-
ness of this policy should also be reconsidered. Since the bias-
adjusted meta-analysis of 10 studies produces a larger treatment
effect estimate (and 95% interval further from the null value) than
the meta-analysis of two studies used in cost-effectiveness
modelling in the NICE appraisals, it is very likely that RAADP
would again be judged cost-effective on the basis of the new
results.
Two of the licensed anti-D treatments have not yet been
evaluated. In a meta-regression analysis, we predicted the
underlying effectiveness odds ratios that we would expect for
these treatments if they were compared against control antenatal
care in a future trial. In the absence of a head-to-head trial
comparing the three licensed treatments directly, this provides
useful information on their expected relative effectiveness. Our
model gave a high probability that a dose of 1250 IU at 28 and 34
weeks would be the most effective amongst the three licensed
treatments, and a high probability that a single dose of 1500 IU at
28–30 weeks would be the least effective. These results could
inform an economic model to compare the expected cost-
effectiveness of the three licensed treatments and determine which
is the optimum dose regimen of RAADP. However, a large
randomised trial comparing the three licensed doses would
provide much firmer evidence on their relative clinical effective-
ness and cost-effectiveness.
When comparing the licensed regimens, we have not taken into
account ethical considerations. Some women are reluctant to
receive blood products and their reluctance may be greater for a
two-dose regimen using larger doses of immunoglobulin. If
problems with availability of anti-D immunoglobulin are encoun-
tered in the future, a regimen which minimises the total volume of
plasma administered would be preferred. New technologies
currently under development could potentially lead to consider-
able changes in the antenatal care of Rhesus negative women.
Recombinant anti -D immunoglobulin is expected to become
available and would provide a safer, more acceptable alternative to
human plasma immunoglobulin. In addition, if antenatal fetal
genotyping becomes widespread and cost-effective, this would
allow targeted antenatal anti-D prophylaxis in pregnancies where
the fetus is found to be Rhesus positive [23].
Without adjustment for variations in study design and quality, it
would be inappropriate to combine evidence from all available
RAADP studies. In comparison with the unadjusted meta-analysis,
the weights given to the studies in calculation of the pooled result
changed considerably after adjustment for biases. In particular, the
weights given to the higher quality studies (MacKenzie [12],
Mayne [13] and Huchet [10]) were increased, while the influence
of lower quality studies was reduced. By adjusting for bias and
acknowledging uncertainty over its impact, we aimed to remove
unexplained between-study heterogeneity from the meta-analysis
[19], and this was achieved in the analysis of the RAADP studies.
The bias-adjustment process relies on incorporating expert
opinion. Subjective judgement is routinely used in meta-analysis.
The standard approach to handling studies of diverse quality and
design is to choose a minimum threshold for inclusion and regard
those studies included as unbiased. By presenting results from both
unadjusted and bias-adjusted meta-analyses, as in this paper,
subjective opinion is made transparent and accountable. The
experts who quantified the biases were carefully chosen for their
knowledge of anti-D prophylaxis (or their quantitative expertise,
for internal biases), and their opinions were combined in such a
way that no individual view could overly influence the final results
of the meta-analysis.
Conclusion
A bias-adjusted synthesis of all available evidence provides
strong evidence for the effectiveness of RAADP in preventing
sensitisation, in support of the policy of offering RAADP to all
non-sensitised pregnant Rhesus negative women. All three licensed
Figure 5. Exploratory analysis comparing different dose regimens. For each of seven RAADP treatment regimens: elicited relative
effectiveness compared to an optimally effective treatment (67% intervals pooled across assessors); observed odds ratios comparing RAADP to
control (with 95% intervals), where available; and odds ratios expected in a future study comparing RAADP to control (with 95% intervals), obtained
from a fitted meta-regression model. (Higher values for relative effectiveness compared to an optimal treatment correspond to lower odds ratios
compared to control.).
doi:10.1371/journal.pone.0030711.g005
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RAADP treatments are expected to be effective in preventing
sensitisation. A dose of 1250 IU at 28 and 34 weeks is expected to
be most effective and a single dose of 1500 IU at 28–30 weeks is
expected to be least effective.
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